Silexion Advances Pancreatic Cancer Trial in Europe, Secures Key Regulatory Milestone
Event summary
- Silexion Therapeutics submitted a Clinical Trial Application (CTA) to Germany’s BfArM for Phase 2/3 trials of SIL204 in locally advanced pancreatic cancer (LAPC).
- Germany will serve as the Reporting Member State for the trial, impacting the entire European Union regulatory process.
- The CTA follows positive Scientific Advice from BfArM (December 2025) and approval from the Israeli Ministry of Health.
- Trial initiation is planned for Q2 2026, with sites planned in Germany and other EU member states alongside Israel.
- SIL204 utilizes a dual-route administration strategy: intratumoral and systemic delivery.
The big picture
Silexion's advancement into the European regulatory landscape represents a significant step for the company, validating its RNAi approach to targeting KRAS mutations—a prevalent driver in multiple cancers. The company's reliance on Germany as the Reporting Member State underscores the EU's increasing harmonization of clinical trial regulations. The success of SIL204 could establish a new paradigm for treating KRAS-driven cancers, a market with a substantial unmet need and potential for significant revenue generation.
What we're watching
- Regulatory Scrutiny
- Germany's rigorous regulatory environment will likely set the precedent for the broader EU approval process, potentially influencing timelines and data requirements for other member states.
- Clinical Execution
- The success of the trial hinges on enrolling patients across multiple EU sites and maintaining the planned dual-route administration strategy, which presents logistical and operational complexities.
- Market Adoption
- Given the high mortality rate and limited treatment options in LAPC, the commercial viability of SIL204 will depend on demonstrating a statistically significant and clinically meaningful benefit over existing chemotherapy regimens.
Related topics